Browse Arkansas Code titles and sections

21 U.S.C. § 1191 to 1193 — Transferred

Federal law — U.S. Code and appendices · legal_authorities

21 U.S.C. § 1191 to 1193 — Transferred

### Statutory Notes #### Codification Section 1191, Pub. L. 92–255, title V, § 501, Mar. 21, 1972, 86 Stat. 85; Pub. L. 93–282, title II, § 204, May 14, 1974, 88 Stat. 136; Pub. L. 94–237, § 12(a), Mar. 19, 1976, 90 Stat. 247; Pub. L. 96–181, § 10, Jan. 2, 1980, 93 Stat. 1314; Pub. L. 97–35, title IX, § 973(f), Aug. 13, 1981, 95 Stat. 598, which established the National Institute on Drug Abuse, was redesignated section 503(a)–(d) of the Public Health Service Act by Pub. L. 98–24, § 2(b)(4), Apr. 26, 1983, 97 Stat. 177, transferred to section 290aa–2(a)–(d) of Title 42, The Public Health and Welfare, and subsequently repealed. Section 1192, Pub. L. 92–255, title V, § 502, as added Pub. L. 94–237, § 12(b)(1), Mar. 19, 1976, 90 Stat. 247; amended Pub. L. 95–461, § 5, Oct. 14, 1978, 92 Stat. 1269; Pub. L. 96–181, § 11, Jan. 2, 1980, 93 Stat. 1315, which related to the coordination, information, assistance, and assignment activities and services, was redesignated section 524 of the Public Health Service Act by Pub. L. 98–24, § 2(b)(15), Apr. 26, 1983, 97 Stat. 181, transferred to [section 290ee of Title 42](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section290ee&num=0&edition=prelim), and subsequently omitted. Section 1193, Pub. L. 92–255, title V, § 503, as added Pub. L. 94–237, § 13(a), Mar. 19, 1976, 90 Stat. 248; amended Pub. L. 95–461, § 2(c), Oct. 14, 1978, 92 Stat. 1268; Pub. L. 96–181, § 12, Jan. 2, 1980, 93 Stat. 1315; Pub. L. 97–35, title IX, § 972(a), (b), Aug. 13, 1981, 95 Stat. 597, which related to research and development functions, was redesignated section 515 of the Public Health Service Act by Pub. L. 98–24, § 2(b)(11), Apr. 26, 1983, 97 Stat. 180, transferred to [section 290cc of Title 42](https://uscode.house.gov/view.xhtml?re

Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 1191 to 1193

Stored review status: release_metadata_unconfirmed. A text match is a research starting point; applicability is not established.

Original supplied file — preserved unchanged

Download original Markdown file

File SHA-256: ad2e728308b2274cb5a98020948b6f967a6a2eb76f6d01b40fdcd3910a5d717b. The original may include catalog metadata, neighboring provisions, or embedded records outside this collection's scope. Search shows only the selected federal record. Historical editions and unverified snapshots are not a statement of current law.

Authority boundary: historical or unconfirmed source not current law verified.

Record provenance

Stable record: federal_law:legal_authorities:record_usc_0386d14ef2933f53ff143f19
Source file: Laws/federal/codes/united-states-code/title-21/section-1191-to-1193-21-u-s-c-1191-to-1193-transferred--a3f4acda47.md
Pages: Not recorded – Not recorded
Passage SHA-256: 7c5e9847b15655a556324a6a59b5a9567845af5baff4e153d61a7baad021432d

Source location: Title 21, Chapter 16, § 1191 to 1193; chapter-016-drug-abuse-prevention-treatment-and-rehabilitation.md

Stored source content

Cross-references

Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.

Federal law — U.S. Code and appendices · legal_authorities

42 U.S.C. § 290ee — Opioid overdose reversal medication access, education, and co-prescribing grant programs

**(a) Grants** The Secretary shall make grants to States, localities, Indian Tribes, and Tribal organizations (as those terms are defined in [section 5304 of title 25](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title25-section5304&num=0&edition=prelim)) to— (1) implement strategies that increase access to drugs or devices approved, cleared, or otherwise legally marketed under the Federal Food, Drug, and Cosmetic Act [[21 U.S.C. 301](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section301&num=0&edition=prelim) et seq.] for emergency treatment of known or suspected opioid overdose, as appropriate, pursuant to a standing order; (2) encourage pharmacies to dispense opioid overdose reversal medication pursuant to a standing order; (3) encourage health care providers to co-prescribe, as appropriate, drugs or devices approved, cleared, or otherwise legally marketed under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose; (4) develop or provide training materials that persons authorized to prescribe or dispense a drug or device approved, cleared, or otherwise legally marketed under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose may use to educate the public concerning— (A) when and how to safely administer such drug or device; and (B) steps to be taken after administering such drug or device; and (5) educate the public concerning the availability of drugs or devices approved, cleared, or otherwise legally marketed under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose without a person-specific prescription. **(b) Certain requirement** A grant may be made under this

Source: Supplied U.S. Code snapshot — release unconfirmed · 42 U.S.C. § 290ee

Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.